abs295.txt	purpose		in	this	era	of	precision-based	medicine	for	optimal	patient	care	results	reported	from	commercial	next-generation	sequencing	(ngs)	assays	shouldadequately	reflect	the	burden	somatic	mutations	tumor	being	sequenced	here	we	sought	to	determine	prevalence	clonal	hematopoiesis	leading	topossible	misattribution	mutation	calls	on	unpaired	foundation	medicinengs	experimental	design	was	a	retrospective	cohort	study	ofindividuals	undergoing	ngs	solid	tumors	two	large	cancer	centers	weidentified	and	quantified	genes	known	be	frequently	altered	inclonal	(dnmt3a	tet2	asxl1	tp53	atm	chek2	sf3b1	cbl	jak2)that	were	returned	physicians	clinical	reports	asubset	patients	explored	frequency	true	bycomparing	with	matched	bloodsequencing	that	are	clonalhematopoiesis	identified	65%	(1	139/1	757)	when	excluding	which	is	often	mutated	these	events	werestill	seen	35%	(619/1	utilizing	paired	blood	specimens	wewere	able	confirm	8%	(18/226)	weretrue	majority	dnmt3a	(64%	7/11)and	minority	(4%	2/50)	conclusions	commonly	testing	itis	important	recognize	as	possible	cause	ofmisattribution	origin	applying	findings	patient's	clin	res	1-7	Â©2018	aacr
